

PRIOR AUTHORIZATION REQUEST FORM

Brand Antiemetics for Chemotherapy Induced Nausea and Vomiting

Akynzeo® (netupitant and palonosetron) Capsules,
 Sancuso® (granisetron) patch, Sustol® (granisetron) subcutaneous injection, Varubi® (rolapitant) tablets,
 Zuplenz® (ondansetron) film

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested:

NK1 antagonist: Varubi® (rolapitant) tablets

5-HT3 antagonists: Sancuso® (granisetron) patch, Sustol® (granisetron) SQ injection, Zuplenz® (ondansetron) film

5-HT3/NK1 combination: Akynzeo® (netupitant/palonosetron) capsules

Dosing/Frequency: _____

Questions	Yes	No	Comments/Notes
AKYNZEO®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member tried and failed aprepitant or fosaprepitant in combination with palonosetron?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
SANCUSO®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • ondansetron • granisetron 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
SUSTOL®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • Ondansetron • Granisetron • Sancuso® patch 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
VARUBI®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member tried and failed aprepitant and fosaprepitant?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
ZUPLENZ®			
1. Is this request for prevention of nausea and vomiting associated with moderately to highly emetogenic intravenous chemotherapy regimens?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member tried and failed all of the following: <ul style="list-style-type: none"> • Ondansetron ODT • Granisetron 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 006
 Origination Date: 06/22/2018
 Reviewed/Revised Date: 08/18/2021
 Next Review Date: 08/18/2022
 Current Effective Date: 09/01/2021

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.